At the time of writing, Clearside Biomedical Inc [CLSD] stock is trading at $1.51, up 8.63%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The CLSD shares have gain 7.09% over the last week, with a monthly amount glided 8.63%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 29, February 2024, Clearside Biomedical to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Corporate Update on Tuesday, March 12, 2024. In a post published today on Yahoo Finance, Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space (SCS®), announced today that its fourth quarter and full year 2023 financial results will be reported on Tuesday, March 12, 2024 after the close of the financial markets. Management will host a webcast and conference call at 4:30 p.m. Eastern Time to discuss the results and provide a corporate update.
From an analyst’s perspective:
Previously, H.C. Wainwright started tracking the stock with Buy rating on July 29, 2021, and set its price target to $10. On May 13, 2020, ROTH Capital initiated with a Buy rating and assigned a price target of $8 on the stock. Needham downgraded its rating to a Hold. Stifel downgraded its rating to a Hold. JP Morgan downgraded its rating to Underweight for this stock on November 05, 2018. In a note dated November 05, 2018, Cowen downgraded an Market Perform rating on this stock.
For the past year, the stock price of Clearside Biomedical Inc fluctuated between $0.65 and $1.54. Clearside Biomedical Inc [NASDAQ: CLSD] shares were valued at $1.51 at the most recent close of the market.
Analyzing the CLSD fundamentals
According to Clearside Biomedical Inc [NASDAQ:CLSD], the company’s sales were 2.21M for trailing twelve months, which represents an 222.93% jump. Gross Profit Margin for this corporation currently stands at 0.74% with Operating Profit Margin at -13.57%, Pretax Profit Margin comes in at -16.88%, and Net Profit Margin reading is -18.13%. To continue investigating profitability, this company’s Return on Assets is posted at -1.16, Equity is 35.51 and Total Capital is -1.05. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.08.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.3570 points at the first support level, and at 1.2040 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6565, and for the 2nd resistance point, it is at 1.8030.
Clearside Biomedical Inc [CLSD] reported earnings per share of -$0.15 for its fiscal quarter that ended on 9/29/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.15/share, meaning a difference of $0 and a surprise factor of 0.00%. By comparison, the stated earnings for the previous quarter ended on 6/29/2023 were -$0.15 per share as compared to estimates of -$0.14 per share, a difference of -$0.01 representing a surprise of -7.10%.
Ratios To Look Out For
It is important to note that Clearside Biomedical Inc [NASDAQ:CLSD] has a current ratio of 5.28. In addition, the Quick Ratio stands at 5.28 and the Cash Ratio stands at 4.94. Considering the valuation of this stock, the price to sales ratio is 51.05.
Transactions by insiders
Recent insider trading involved WHITMORE BRADFORD T, 10% Owner, that happened on Feb 07 ’24 when 0.44 million shares were purchased. CEO, LASEZKAY GEORGE M completed a deal on Jan 19 ’24 to sell 18000.0 shares. Meanwhile, Chief Financial Officer Deignan Charles A. sold 12900.0 shares on Jan 19 ’24.
